PubMed:27172902 / 1213-1467
Annnotations
LitCoin-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T7 | 0-254 | Sentence | denotes | Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity. |
LitCoin-entities
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| 11308 | 45-54 | ChemicalEntity | denotes | cisplatin | MESH:D002945 |
| 11309 | 59-77 | ChemicalEntity | denotes | lipopolysaccharide | MESH:D008070 |
| 11310 | 79-82 | ChemicalEntity | denotes | LPS | MESH:D008070 |
LitCoin-GeneOrGeneProduct-v0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T39 | 45-54 | GeneOrGeneProduct | denotes | cisplatin |
| T40 | 137-149 | GeneOrGeneProduct | denotes | inducing the |
| T41 | 167-170 | GeneOrGeneProduct | denotes | Th1 |
| T42 | 188-193 | GeneOrGeneProduct | denotes | cells |
| T43 | 240-244 | GeneOrGeneProduct | denotes | cell |
| T44 | 245-253 | GeneOrGeneProduct | denotes | immunity |
LitCoin-GeneOrGeneProduct-v2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T21 | 45-54 | GeneOrGeneProduct | denotes | cisplatin |
| T22 | 240-244 | GeneOrGeneProduct | denotes | cell |
| T23 | 245-253 | GeneOrGeneProduct | denotes | immunity |
LitCoin_Mondo_095
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T10 | 15-18 | DiseaseOrPhenotypicFeature | denotes | DCs | 0010155 |
| T11 | 79-82 | DiseaseOrPhenotypicFeature | denotes | LPS | 0019508 |
| T12 | 210-213 | DiseaseOrPhenotypicFeature | denotes | DCs | 0010155 |
LitCoin-Chemical-MeSH-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T15 | 45-54 | ChemicalEntity | denotes | cisplatin | D002945|http://purl.obolibrary.org/obo/CHEBI_27899 |
| T17 | 59-77 | ChemicalEntity | denotes | lipopolysaccharide | D008070|http://purl.obolibrary.org/obo/CHEBI_16412 |
| T19 | 79-82 | ChemicalEntity | denotes | LPS | http://purl.obolibrary.org/obo/CHEBI_89981|http://purl.obolibrary.org/obo/CHEBI_52603|http://purl.obolibrary.org/obo/CHEBI_16412|D008070 |
LitCoin-training-merged
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T19 | 79-82 | ChemicalEntity | denotes | LPS | D008070|http://purl.obolibrary.org/obo/CHEBI_16412|http://purl.obolibrary.org/obo/CHEBI_52603|http://purl.obolibrary.org/obo/CHEBI_89981 |
| T17 | 59-77 | ChemicalEntity | denotes | lipopolysaccharide | http://purl.obolibrary.org/obo/CHEBI_16412|D008070 |
| T15 | 45-54 | ChemicalEntity | denotes | cisplatin | http://purl.obolibrary.org/obo/CHEBI_27899|D002945 |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T7 | 0-254 | Sentence | denotes | Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity. |
| T7 | 0-254 | Sentence | denotes | Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity. |